Prodigy - the UK government's much-criticised computerised decision-support system - came under fire again recently. The Association of the British Pharmaceutical Industry (ABPI) gave Prodigy's critics new ammunition by warning in a report that the limited choice of triptans on the system may mean that some patients with migraine might not receive the most appropriate treatment. Indeed, the ABPI's director-general called the system'deeply-flawed',its advice to prescribe only 1 of the triptans currently on the UK market as'quite unacceptable',and argued that Prodigy conspires against the best interests of patients, business and the country.